AMLX
Amylyx Pharmaceuticals, Inc.Company Information
- Company Name
- Amylyx Pharmaceuticals, Inc.
- CIK
- CIK0001658551
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- AMLX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- AMLX
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-05-21
- Last sale
- 2026-03-02
- Shares purchased (TTM)
- 11,900
- Shares sold (TTM)
- 256,840
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 113,531,472
- Shares outstanding
- 110,563,360
- Ownership
- 102.68%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 43.61%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 49 | 229 | 227 | 225 | 58 | 60 | 77 | 72 | 75 | 171 | 170 | 135 | ||||||
| Short Term Investments | - | - | - | - | - | - | - | - | 235 | 203 | 201 | 220 | ||||||
| Marketable Securities Current | 201 | 51 | 90 | 119 | 123 | 144 | 99 | 163 | - | - | 201 | - | ||||||
| Accounts Receivable Net Current | - | - | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 20 | 40 | 29 | ||||||
| Inventory Net | - | - | - | - | - | - | - | - | - | - | 38 | 32 | ||||||
| Prepaid Expense And Other Assets Current | 6 | 5 | 7 | 9 | 6 | 12 | 12 | 9 | 13 | 17 | 15 | 17 | ||||||
| Assets Current | 256 | 285 | 324 | 353 | 187 | 216 | 189 | 245 | 327 | 411 | 465 | 434 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | ||||||
| Restricted Cash Equivalents Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 5 | 5 | 5 | 5 | 6 | 1 | 2 | 5 | 3 | 3 | 4 | 4 | ||||||
| Inventory Noncurrent | - | - | - | - | - | - | - | - | - | - | 45 | 24 | ||||||
| Other Assets Noncurrent | - | 3 | - | 3 | - | 0 | 0 | 0 | 0 | 0 | 1 | 0 | ||||||
| Assets | 265 | 294 | 333 | 363 | 195 | 220 | 194 | 251 | 332 | 417 | 517 | 467 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 6 | 4 | 4 | 5 | 3 | 5 | 3 | 1 | 5 | 21 | 22 | 6 | ||||||
| Accrued Liabilities Current | 15 | 11 | 18 | 19 | 17 | 12 | 24 | 50 | 63 | 68 | 58 | 37 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Liabilities Current | 21 | 16 | 23 | 26 | 21 | 18 | 28 | 54 | 70 | 92 | 82 | 46 | ||||||
| Operating Lease Liability Noncurrent | 4 | 4 | 5 | 5 | 5 | 0 | 0 | 1 | 1 | 1 | 2 | 3 | ||||||
| Liabilities | 25 | 20 | 27 | 31 | 27 | 18 | 29 | 55 | 71 | 93 | 84 | 48 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 1,075 | 1,066 | 1,056 | 1,050 | 851 | 844 | 772 | 765 | 758 | 748 | 738 | 728 | ||||||
| Retained Earnings Accumulated Deficit | -836 | -793 | -751 | -718 | -684 | -643 | -607 | -569 | -496 | -424 | -305 | -310 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 1 | 1 | 0 | -0 | 1 | -0 | -0 | 0 | -0 | ||||||
| Stockholders Equity | 239 | 273 | 305 | 332 | 168 | 201 | 165 | 196 | 261 | 324 | 433 | 418 | ||||||
| Liabilities And Stockholders Equity | 265 | 294 | 333 | 363 | 195 | 220 | 194 | 251 | 332 | 417 | 517 | 467 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | - | 10 | 10 | 10 | - | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | ||||||
| Common Stock Shares Issued | 111 | 111 | 110 | 110 | 89 | 89 | 69 | 69 | 68 | 68 | 68 | 68 | ||||||
| Shares Outstanding | 111 | 111 | 110 | 110 | 89 | 89 | 69 | 69 | 68 | 68 | 68 | 68 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAmylyx Pharmaceuticals, Inc. (AMLX) — SEC Financial Statements & Analysis
Amylyx Pharmaceuticals, Inc. (AMLX) is a pharmaceutical preparations company, incorporated in DE. Amylyx Pharmaceuticals, Inc. trades on Nasdaq as: AMLX. Amylyx Pharmaceuticals, Inc. (AMLX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Amylyx Pharmaceuticals, Inc. carries a market cap of $2.00B, a P/E ratio of -13.13x, a P/B ratio of 8.35x, a P/S ratio of -1907.36x, an enterprise value of $1.95B, and an EV/EBITDA multiple of -12.04x. On profitability, it posts a gross margin of 89.49%, an operating margin of 23660.30%, a net margin of 22448.42%, a Return on Equity (ROE) of -74.73%, a Return on Assets (ROA) of -66.25%, and a Return on Invested Capital (ROIC) of -108.20%. Per share, it reports EPS of $-1.37, diluted EPS of $-1.37, free cash flow per share of $-1.14, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -18.93% year-over-year, and EPS growth of -35.01% year-over-year. On the balance sheet, it maintains a current ratio of 12.12x, a quick ratio of 11.86x, working capital of $235.19M, a debt-to-equity ratio of 0.11x, a debt ratio of 0.1, free cash flow of $-126.72M (TTM), and net debt of $-49.33M. Figures sourced from SEC EDGAR.
- Market Cap
- $2.00B
- P/E TTM
- -13.13x
- EPS TTM
- $-1.37
- P/B TTM
- 8.35x
- ROE TTM
- -74.73%
- ROA TTM
- -66.25%
- Debt To Equity
- 0.11x
- Free Cash Flow TTM
- $-126.72M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Amylyx Pharmaceuticals, Inc. in?
Amylyx Pharmaceuticals, Inc. (AMLX) operates in the Pharmaceutical Preparations industry.
What exchange does AMLX trade on?
Amylyx Pharmaceuticals, Inc. (AMLX) trades on the Nasdaq.
Where is Amylyx Pharmaceuticals, Inc. incorporated?
Amylyx Pharmaceuticals, Inc. is incorporated in DE.
When was Amylyx Pharmaceuticals, Inc. (AMLX)'s most recent SEC filing?
Amylyx Pharmaceuticals, Inc. (AMLX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is AMLX's market cap?
Amylyx Pharmaceuticals, Inc. (AMLX) has a market capitalization of $2.00B as of 2026-06-30.
What is AMLX's EPS (earnings per share)?
Amylyx Pharmaceuticals, Inc. (AMLX)'s trailing twelve month EPS is $-1.37 as of 2026-06-30.
What is AMLX's ROE (return on equity)?
Amylyx Pharmaceuticals, Inc. (AMLX)'s trailing twelve month Return on Equity (ROE) is -74.73% as of 2026-06-30.
What is AMLX's ROA (return on assets)?
Amylyx Pharmaceuticals, Inc. (AMLX)'s trailing twelve month Return on Assets (ROA) is -66.25% as of 2026-06-30.
What is AMLX's ROIC (return on invested capital)?
Amylyx Pharmaceuticals, Inc. (AMLX)'s trailing twelve month Return on Invested Capital (ROIC) is -108.20% as of 2026-06-30.
What is AMLX's EV/EBITDA?
Amylyx Pharmaceuticals, Inc. (AMLX)'s trailing twelve month EV/EBITDA is -12.04x as of 2026-06-30.